Core Viewpoint - The approval of oral GLP-1 weight loss drugs is leading to significant structural changes in the U.S. food and beverage industry, making weight loss medications more accessible to a broader consumer base, which in turn is altering consumer behavior and food consumption patterns [5]. Group 1: Impact on Consumer Behavior - The introduction of oral GLP-1 medications is expected to lower the barriers for usage, allowing more consumers to enter the weight loss medication market, thus shifting the focus from high-calorie foods to those with higher nutritional value [5]. - A study from Cornell University indicates that households using GLP-1 medications have seen grocery spending decrease by over 5%, with fast food consumption dropping nearly 8%, suggesting a shift towards quality over quantity in food choices [7]. Group 2: Industry Response - Food companies are proactively adjusting their product offerings in response to these changes. For instance, ConAgra has enhanced the high-protein and high-fiber attributes of its Healthy Choice frozen meals, targeting GLP-1 users, resulting in faster sales growth compared to competitors [7]. - Danone reported double-digit growth in its high-protein yogurt products, with this trend expected to accelerate as the usage of weight loss medications increases [7]. - Nestlé has launched a frozen meal series specifically for GLP-1 users, focusing on nutrient density rather than quantity, and optimizing retail displays in collaboration with large supermarkets [7]. Group 3: Restaurant Industry Adaptation - The restaurant sector is also adapting, with Chipotle introducing high-protein menu options and traditional chains offering smaller portion sizes at lower prices, reflecting a consumer shift towards more mindful eating habits [8]. - The adjustments in the restaurant industry indicate a consensus that consumers are not abandoning dining out but are becoming more selective and health-conscious in their choices [8]. Group 4: Long-term Implications - The widespread adoption of GLP-1 medications is seen as a long-term force reshaping consumer behavior, leading to a demand for foods that provide clear health benefits within limited caloric intake [8]. - Companies are urged to recalibrate their growth strategies, as the question of which foods remain desirable in the context of weight loss medications will be crucial for the industry's future [8].

据报道，礼来公司自己的口服减肥药预计将在明年3月获批。这意味着诺和诺德拥有了几个月的宝贵窗 口期，以巩固其在口服药市场的首发优势。 智通财经APP获悉，周二，诺和诺德(NVO.US)盘前涨超8%，报52.29美元。消息面上，美国FDA批准了 诺和诺德的首款口服GLP-1减肥药，使其在与礼来的竞争中抢得先机。这款Wegovy的口服版本将于明 年1月初在美国上市，起始现金价为每月149美元。临床数据显示其可帮助患者减重高达16.6%，并能降 低心血管风险。 ...